Thsi section focuses on the evolving landscape of CAR-T cell therapy for multiple myeloma, particularly BCMA-targeted treatments and next-generation cellular therapies. We share updates on clinical trials, long-term remission data, combination strategies, and access pathways in China and worldwide. Stay informed on how CAR-T is transforming treatment options for relapsed or refractory multiple myeloma.
CAR-T therapy is no longer being explored only for relapsed or refractory multiple myeloma. New research is investigating its use in newly diagnosed and high-risk patients, with the potential to achieve deeper and more durable remissions.
OL-101, a novel BCMA/GPRC5D dual-target CAR-T cell therapy, achieved 100% ORR and deep responses in a Phase I study of heavily pretreated R/R multiple myeloma patients, including those with prior CAR-T exposure and extramedullary disease, presented at EHA 2026.
CAR-T cell therapy, antibody-drug conjugates (ADCs), and bispecific antibodies are transforming the treatment landscape for multiple myeloma. Discover how these innovative immunotherapies work and the benefits they offer patients with relapsed or refractory disease.
As CAR-T therapy reshapes treatment for multiple myeloma worldwide, China is emerging as a key alternative with strong research, lower costs, and faster access.
On November 3, new clinical data were released for a universal BCMA-targeted CAR-T therapy candidate (CT0596) in patients with relapsed/refractory multiple myeloma (R/R MM). The results show favorable preliminary safety
Multiple myeloma (MM), a malignant plasma cell disorder, continues to pose major treatment challenges for patients with relapsed or refractory disease (R/R MM), despite continuous advances in therapeutic options. While
Eque-cel CAR-T Therapy Shows Durable Efficacy and Strong Safety Profile in Heavily Pretreated Multiple Myeloma Patients
Long-term follow-up results from the Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, an autologous CAR T-cell product targeting BCMA) were recently presented as a poster at the 22nd International
Learn how BCMA CAR-T therapy works to treat multiple myeloma. This easy-to-understand guide explains benefits, side effects, and what patients can expect from this breakthrough immunotherapy.
Multiple myeloma (MM) remains an incurable blood cancer with high relapse and drug resistance rates. Discover how emerging immunotherapies are reshaping treatment and offering new hope for patients.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.